Financial Data and Key Metrics Changes - Total revenue for 2025 was $106 million, up from $76.3 million in 2024, driven by significant clinical and regulatory milestones and collaboration options [27] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, primarily due to a non-recurring impairment charge in 2024 [28][29] - Net loss improved to $81.1 million in 2025 compared to a net loss of $122.7 million in 2024, attributed to increased revenue and decreased operating expenses [30] Business Line Data and Key Metrics Changes - Revenue growth was partially offset by a decline in development support and drug supply-related revenue from Jazz, reflecting a transition of responsibilities under collaboration agreements [27] - The company reported regulatory approvals for Zanidatamab as monotherapy in Canada and the UK for second-line biliary tract cancer, which is expected to translate into regulatory milestone payments of up to $440 million [12][13] Market Data and Key Metrics Changes - Consensus estimates for peak sales of Zanidatamab have doubled, indicating potential for multi-billion dollar peak sales levels [12] - The company expects cumulative revenue contributions through royalties and milestones to scale significantly as use broadens across indications and geographies [14] Company Strategy and Development Direction - The company aims to leverage a validated scaling asset to secure efficient non-dilutive capital while preserving long-term upside [15][16] - A strategic financing agreement with Royalty Pharma provides $250 million of low-cost non-dilutive capital, allowing for accelerated reinvestment into new value-generating assets [16][18] - The company plans to continue conducting phase 1 clinical studies for ZW191 and ZW251 in 2026, with a focus on integrating new partnerships and collaborations into its existing portfolio [36][37] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding Zanidatamab's potential to redefine treatment paradigms in first-line HER2-positive metastatic or locally advanced GEA, with strong feedback from key opinion leaders [7][9] - The company anticipates significant opportunities to build financial value through regulatory approvals and milestone payments, with a cash runway extending beyond 2028 [31][32] Other Important Information - The company has approximately $270.6 million in cash resources as of December 31, 2025, down from $324.2 million in 2024 [30] - Adjusted gross operating expenses are expected to be approximately 20% lower in 2026 compared to 2025, excluding acquisition-related expenses [32] Q&A Session Summary Question: Regarding GPC3 ADC ZW251 enrollment and internal decision-making - Management indicated that enrollment for ZW251 is proceeding as planned, with a similar operational execution expected as seen in ZW191 [44][46] Question: Timing of royalty-backed financing and acquisition opportunities - The timing for the royalty note completion was influenced by the commercialization cycle of Zanidatamab and the current cost of capital [52][54] Question: Types of assets targeted for acquisitions - The company is looking for innovative medicines that drive dramatic patient benefits, with a focus on oncology and immunology, but not limited to these areas [73][77] Question: Details on the 20% reduction in operating expenses and share repurchase cadence - Management confirmed that the share repurchase program is progressing well, with expectations of utilizing available capital for further repurchases as opportunities arise [84][86]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $106 million, up from $76.3 million in 2024, driven by significant clinical and regulatory milestones and collaboration options [25] - Operating expenses decreased to $198.5 million in 2025 from $213.4 million in 2024, primarily due to a non-recurring impairment charge in 2024 [26] - Net loss improved to $81.1 million in 2025 compared to a net loss of $122.7 million in 2024, attributed to increased revenue and decreased operating expenses [27] - Cash resources as of December 31, 2025, were $270.6 million, down from $324.2 million in 2024 [27] Business Line Data and Key Metrics Changes - Revenue growth was partially offset by a decline in development support and drug supply-related revenue from Jazz, reflecting a transition of responsibilities under the collaboration agreement [25] - The company reported regulatory approvals for zanidatamab as monotherapy in Canada and the UK for second-line biliary tract cancer, with potential milestone payments of up to $440 million for global approvals in GEA [10][11] Market Data and Key Metrics Changes - Consensus estimates for peak sales of zanidatamab have doubled, indicating potential for multi-billion dollar peak sales levels [10] - The company expects cumulative revenue contributions through royalties and milestones to scale meaningfully as use broadens across indications and geographies [11] Company Strategy and Development Direction - The company aims to leverage partnerships to accelerate the development of zanidatamab and broaden its therapeutic potential while sharing development risks [7][8] - A strategic financing agreement with Royalty Pharma provides $250 million of low-cost non-dilutive capital to fund future operations and acquisitions [13][14] - The company plans to integrate new partnerships and collaborations into its existing portfolio to share funding and risk [35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding zanidatamab's potential to redefine treatment paradigms in first-line HER2-positive metastatic or locally advanced GEA [5][6] - The company anticipates continued discipline in capital allocation and expects adjusted gross operating expenses in 2026 to be approximately 20% lower than in 2025 [30] - Management highlighted the importance of maintaining a robust R&D operation while integrating partnerships to enhance the portfolio [86] Other Important Information - The company is actively enrolling patients in the phase 1 study of ZW251, with expectations for approximately 100 patients through dose escalation [32] - The company has a cash runway extending beyond 2028, not accounting for potential acquisitions or new partnerships [72] Q&A Session Summary Question: Update on ZW251 enrollment and internal decision-making - Management indicated that enrollment for ZW251 is proceeding as planned, with a similar operational execution expected as seen in ZW191 [42][47] Question: Timing of royalty-backed financing and acquisition opportunities - Management clarified that the timing for the royalty note completion was influenced by the commercialization cycle of zanidatamab and the current cost of capital [51][52] Question: Expectations for AACR and internal R&D updates - Management hinted at significant updates on multispecifics and ADC capabilities at the upcoming AACR conference [55][58] Question: Insights on pasritamig and PTK7 development - Management expressed enthusiasm for pasritamig's safety and efficacy profile, while also discussing the strategic advantages of the biparatopic design for PTK7 [62][65]

Making a meaningful difference A royalty-driven organization differentiated by in-house R&D capabilities developing novel medicines for patients with difficult-to-treat diseases MARCH 2026 Legal disclaimer This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forwa ...

分组1 - Zymeworks Inc. reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, marking an earnings surprise of -58.64% [1] - The company posted revenues of $2.52 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 88.23%, compared to revenues of $31.03 million a year ago [2] - Zymeworks shares have declined approximately 11.6% since the beginning of the year, while the S&P 500 has gained 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.21 on revenues of $57.98 million, and for the current fiscal year, it is $0.65 on revenues of $267.81 million [7] - The Medical - Biomedical and Genetics industry, to which Zymeworks belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Product Development and Clinical Trials - Zymeworks is focused on developing multifunctional biotherapeutics for difficult-to-treat conditions, including cancer, inflammation, and autoimmune diseases[25]. - Pasritamig, a bispecific T cell engager, is undergoing multiple Phase 3 clinical trials for castration-resistant prostate cancer, initiated by Johnson & Johnson[40]. - Zymeworks is currently recruiting for a Phase 1 clinical trial of ZW191, an ADC targeting FRα-expressing tumors, with an expected enrollment of approximately 145 participants[46]. - ZW251, a clinical-stage ADC targeting GPC3 in HCC, has shown anti-tumor activity in preclinical studies and achieved a highest non-severely toxic dose of 100 mg/kg in non-human primates, indicating potential for high doses in humans[47]. - The ongoing global Phase 1 study of ZW251 aims to enroll approximately 100 participants with advanced solid tumors, including HCC, across North America, Europe, and the Asia-Pacific region[47]. - ZW220 targets NaPi2b-expressing NSCLC and ovarian cancer, demonstrating strong anti-tumor activity in preclinical models and a maximum tolerated dose of ≥90 mg/kg in non-human primates[48]. - The company has paused preparations for a Phase 1 study of ZW220 to prioritize the accelerated development of ZW251, while ZW220 remains IND-ready with strong clinical and commercial potential[49]. - ZW1528, a bispecific molecule targeting IL-4Rα and IL-33, is expected to enter Phase 1 clinical studies in 2026, aiming to address respiratory inflammation in conditions like COPD[51]. - The ADC portfolio includes ongoing Phase 1 studies for ZW191 and ZW251 during 2026, with potential clinical development for ZW220, ZW327, and ZW418 contingent on external funding[53]. - The Azymetric platform has been validated by the FDA approval of zanidatamab in 2024, enabling the development of bispecific and trispecific antibodies with enhanced targeting and efficacy[56]. - The FDA has granted two Fast Track designations to zanidatamab for the first-line treatment of patients with HER2-overexpressing gastroesophageal adenocarcinoma and for previously treated or recurrent gene-amplified BTC[148]. - The FDA has designated zanidatamab as a Breakthrough Therapy for HER2 gene-amplified BTC patients who have received prior systemic chemotherapy[149]. - The FDA has granted Orphan Drug Designation to zanidatamab for the treatment of BTC and GEA, providing benefits such as tax credits for clinical testing expenses and seven years of orphan drug exclusivity[155][156]. Financial Performance and Milestones - The company expects to receive up to $440 million in near-term milestone payments related to zanidatamab approvals in various regions, including $250 million from the U.S.[36]. - Zymeworks has a royalty portfolio that includes tiered royalties of 10% to high teens on global annual net sales of zanidatamab up to $2 billion, and 20% on sales above that threshold[38]. - The company received $69.9 million in milestone payments and fees from collaboration partners in 2025, primarily related to legacy platform collaboration agreements[41]. - Through collaborations with Jazz and BeOne, the company has received $491.0 million in non-refundable upfront and milestone payments, with potential future payments of up to $1.51 billion[64]. - As of December 31, 2025, the company has received a total of $50 million in upfront payments and $325 million in milestone payments from Jazz Pharmaceuticals under the Jazz Collaboration Agreement[76]. - The company is eligible to receive up to $500 million in regulatory milestone payments and up to $862.5 million in potential commercial milestone payments from Jazz Pharmaceuticals[76]. - Under the Zanidatamab Agreement with BeOne, the company has received $40 million in upfront payments and $51 million in milestone payments as of December 31, 2025[80]. - The company remains eligible to receive up to $144 million in development and commercial milestone payments from BeOne, along with tiered royalties of up to 19.5% of annual net sales in BeOne territories[80]. - As of December 31, 2025, the company has received $233.4 million in non-refundable upfront and milestone payments from platform partnership agreements[83]. - The company is eligible to receive up to $0.98 billion in preclinical and development milestone payments and up to $3.08 billion in commercial milestone payments from its strategic partnerships[83]. - BMS has exercised two commercial license options, resulting in $15 million of option payments, with the company remaining eligible for up to $313 million for the two remaining programs[84]. - The agreement with GSK allows for up to $1.1 billion in potential payments, including $110.0 million in milestone payments for each product[88]. - As of December 31, 2025, the company has received $6.0 million in upfront technology access fees and $16.5 million in milestone payments from GSK[89]. - The collaboration with Daiichi Sankyo includes an upfront technology access fee of $2.0 million and option-related payments totaling $4.5 million[90]. - The 2018 agreement with Daiichi Sankyo allows for up to $484.7 million in milestone payments, with $18.0 million received as of December 31, 2025[92]. - The collaboration with J&J includes potential payments of up to $1.45 billion, with $50.0 million received upfront and $33.0 million in development milestones[94]. - The company is eligible for up to $419.3 million in option exercise fees and milestone payments from Merck[97]. Regulatory and Compliance Challenges - Regulatory authorities will review clinical results to determine the effectiveness of Zymeworks' product candidates, with no current approvals granted[139]. - The FDA requires extensive reporting, monitoring, and auditing of all clinical activities, clinical data, and clinical study investigators during all phases of clinical development[143]. - The FDA may deny approval of a BLA if it does not satisfy regulatory criteria, issuing a complete response letter detailing specific deficiencies[153]. - The FDA conducts inspections of manufacturing facilities to ensure compliance with cGMP requirements before approving a BLA[151]. - The process for obtaining regulatory approvals in Canada requires substantial time and financial resources, including compliance with cGMP, GLP, and cGCP[164]. - The process for conducting clinical trials in Canada requires a Clinical Trial Application (CTA) to be submitted, with specific regulations for biological drugs due to their complexity and manufacturing variability[166]. - Upon successful completion of Phase 3 clinical trials, a New Drug Submission (NDS) is required, which includes detailed data on pharmacology, chemistry, and manufacturing[170]. - The approval process for an NDS can take several years and requires substantial financial resources, with potential delays due to varying interpretations of clinical data[171]. - Health Canada may impose restrictions on approved products, including limitations on indications for use and requirements for post-approval studies[172]. - Proposed amendments to the Food and Drug Regulations for biologic drugs were finalized in 2024, with new provisions coming into force on July 1, 2025[172]. - The Canadian regime for biosimilars allows for reliance on prior safety and efficacy information, differing from the approval process for generic drugs[175]. Market and Competitive Landscape - The company faces intense competition from major pharmaceutical and biotechnology companies, which may have greater financial resources and expertise[130]. - The company is developing multiple product candidates targeting various solid tumors, including ZW191 for FRα and ZW251 for GPC3, with competing therapies identified[135][136]. - The company has a license agreement with Phanes Therapeutics, which includes milestone payments and potential royalties on net sales of products incorporating Phanes' intellectual property[121][122]. - The pharmaceutical industry faces pricing pressures due to managed healthcare trends and legislative proposals, impacting the ability to maintain adequate pricing for products[185]. - The Inflation Reduction Act of 2022 allows for federal negotiation of drug prices, which could significantly affect the pharmaceutical industry and pricing strategies[188]. - Coverage and reimbursement for drug products vary significantly by payor, with potential challenges in obtaining adequate reimbursement rates[184]. - Future healthcare reforms may lead to more rigorous coverage criteria and lower reimbursement rates, impacting revenue generation and profitability[189]. Company Operations and Strategy - The company’s capital allocation strategy balances long-term growth investments with stockholder returns, including potential stock repurchases[31]. - Zymeworks aims to enhance asset value through strategic acquisitions of high-quality programs and technologies that align with its objectives[32]. - The company plans to establish additional partnerships with biotechnology and pharmaceutical companies to access the sales, marketing, and distribution capacity required to market its drug candidates[193]. - The company is evolving its business strategy to enhance long-term stockholder value through a royalty-driven asset aggregation strategy, which is unproven and may not be successful[204]. - The company relies on third-party manufacturers for the production of its product candidates and may encounter difficulties that could delay or impair its ability to initiate or complete clinical trials or commercialize products[207]. - The company faces intense competition from larger companies in acquiring or in-licensing promising assets, which may require paying higher prices and affect the return on acquisitions[209]. - The outcome of clinical trials is inherently uncertain, and the company may not satisfy the requirements of regulatory authorities, which could delay or prevent commercialization[210]. - The company has no current intention to commercialize any of its product candidates independently, retaining the flexibility to reevaluate this decision if beneficial for stockholders[193]. - The company is committed to providing equal opportunities for its employees and ensuring good representation from the communities in which it operates[196]. - The company announced the discontinuation of the clinical development program for ZW171 after completing the planned cohorts of the Phase 1 trial, determining that further evaluation would not support a favorable benefit-risk profile[213]. - The company may discontinue the development of certain product candidates to align with a shift in corporate strategy, despite positive clinical results[213]. - The company focuses on specific research programs and therapeutic platforms due to limited financial and managerial resources, potentially delaying other opportunities with greater commercial potential[214]. - The company faces risks in successfully building a pipeline of product candidates, with potential candidates possibly not being safe or effective, which could harm financial position and stock price[215]. - Regulatory approval and commercialization of product candidates depend on various factors, including clinical advancement and regulatory submission processes, which are often beyond the company's control[216]. - The company is subject to economic, political, and regulatory risks associated with international operations, which could materially impact its business and financial condition[217]. - Recent U.S. tariffs and trade policies may adversely affect the company's operations, including increased costs and supply chain disruptions[222]. - Public health outbreaks and pandemics could disrupt clinical trials and business activities, negatively impacting liquidity and increasing market volatility[223]. - The company relies on collaborative relationships with partners like Jazz for the development and commercialization of zanidatamab, with financial returns dependent on their performance[224]. Workforce and Employment - As of December 31, 2025, the company had 264 full-time employees, with 204 engaged in research and development activities, and 60 holding an M.D. or Ph.D. degree[194]. - The company has incurred significant losses since inception and anticipates continuing to incur losses for the foreseeable future, with only one product approved for commercial sale and no revenue from product sales as of December 31, 2025, other than royalties from zanidatamab[207].

Core Viewpoint - Royalty Pharma has entered into a $250 million funding agreement with Zymeworks, providing non-recourse royalty-backed financing based on future royalties from Ziihera, a promising cancer therapy [1][2]. Transaction Overview - Zymeworks will receive $250 million through a non-recourse royalty-backed note, with repayments secured by 30% of future royalties from Ziihera sales [3][8]. - The repayment will cease once Royalty Pharma receives cumulative payments of either 1.65 times the note amount by December 31, 2033, or 1.925 times the note amount thereafter [3]. Royalty Structure - Under the collaboration with Jazz Pharmaceuticals, Zymeworks is eligible for tiered royalties of 10% to high teens on global sales of Ziihera up to $2 billion, and 20% on sales exceeding $2 billion [4]. - The collaboration with BeOne Medicines allows Zymeworks to receive mid-single to mid-double digit royalties on sales up to $1 billion, and 19.5% on sales above that threshold [5]. Financial Implications - Zymeworks will retain 70% of royalties on Ziihera sales during the repayment period, with full rights reverting to Zymeworks once payments to Royalty Pharma cease [6][8]. - The funding will enhance Zymeworks' balance sheet with non-dilutive capital, supporting stock repurchase programs and strategic acquisitions, while extending its cash runway beyond 2028 [2][8]. Product Information - Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody indicated for treating adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer [10]. - The therapy has received accelerated approval from the U.S. FDA based on its overall response rate and duration of response, with continued approval contingent on further clinical trials [10]. Development and Regulatory Status - Ziihera is being developed in multiple clinical trials for solid tumors expressing HER2, with significant milestone payments tied to future regulatory approvals [11][12]. - The FDA has granted Breakthrough Therapy designations for Ziihera in specific cancer indications, highlighting its potential in the treatment landscape [12].

Core Insights - Royalty Pharma and Zymeworks have entered into a $250 million funding agreement, structured as a non-recourse royalty-backed note, with repayments tied to 30% of worldwide tiered royalties from Ziihera [1][3][8] - The funding aims to support Zymeworks' strategic and financial goals, including stock repurchase programs and potential acquisitions, while allowing Royalty Pharma to participate in the long-term value of Ziihera [2][8] Transaction Details - Zymeworks will receive $250 million through a non-recourse royalty-backed note, with repayment secured by 30% of future royalties from Ziihera sales, which will tier up to a specified repayment limit [3][8] - Royalty Pharma will stop receiving royalties once cumulative payments reach either 1.65 times the note amount by December 31, 2033, or 1.925 times the note amount thereafter [3] Royalty Structure - Under the collaboration with Jazz, Zymeworks is eligible for tiered royalties of 10% to high teens on global sales of Ziihera up to $2 billion, and 20% on sales exceeding that amount [4] - The collaboration with BeOne allows Zymeworks to receive mid-single to mid-double digit royalties on sales up to $1 billion, and 19.5% on sales above that threshold [5] Financial Implications - Zymeworks will retain 70% of royalties on Ziihera sales during the repayment period, with full rights reverting to Zymeworks once payments to Royalty Pharma cease [6][8] - The agreement is expected to strengthen Zymeworks' balance sheet with non-dilutive capital, enhancing its capacity for strategic acquisitions and extending its cash runway beyond 2028 [2][8] Product Information - Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody indicated for treating adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer [10] - The drug is being developed in multiple clinical trials for various solid tumors expressing HER2, with significant milestone payments tied to future regulatory approvals [11][12]

Core Viewpoint - Zymeworks Inc. has entered into a $250 million funding agreement with Royalty Pharma, which will be structured as a non-recourse royalty-backed note, with repayments tied to 30% of worldwide tiered royalties from Ziihera® sales [1][2][3]. Funding Agreement - The agreement provides Zymeworks with non-dilutive capital, enhancing its flexibility for share repurchases and strategic acquisitions, while supporting its cash runway beyond 2028 [2][8]. - Royalty Pharma will receive repayments based on 30% of future royalties from Ziihera sales until cumulative payments reach either 1.65 times the note amount by December 31, 2033, or 1.925 times thereafter [3]. Royalty Structure - Zymeworks will retain 70% of royalties on Ziihera sales during the repayment period, with full rights reverting to Zymeworks once payments to Royalty Pharma cease [6][8]. - Under the collaboration with Jazz Pharmaceuticals, Zymeworks is eligible for tiered royalties of 10% to high teens on global sales up to $2 billion, and 20% on sales exceeding that amount [4]. - The collaboration with BeOne Medicines allows Zymeworks to receive mid-single to mid-double digit royalties on sales up to $1 billion, and 19.5% on sales above that threshold [5]. Milestone Payments - Zymeworks is set to retain all earned regulatory and commercial milestone payments, which could total up to $1.5 billion, including $440 million tied to future regulatory approvals for Ziihera [6][8]. Product Overview - Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody indicated for treating adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer [10]. - The FDA has granted Ziihera Breakthrough Therapy designations for specific indications, highlighting its potential in treating difficult cancers [11]. Company Background - Zymeworks is a biotechnology company focused on developing novel biotherapeutics for challenging diseases, leveraging its proprietary Azymetric™ technology [12]. - Royalty Pharma is a leading buyer of biopharmaceutical royalties, funding innovation across the industry and holding a diverse portfolio of royalties from various commercial products [13][14].

Core Insights - Zymeworks Inc. has redefined its strategy focusing on long-term value creation through disciplined capital allocation and a growing royalty portfolio, aiming for sustainable shareholder returns [2][3] - The company reported a total revenue of $106.0 million for 2025, a 39% increase from 2024, and reduced its net loss by 34% to $81.1 million [20][24] - A $250.0 million royalty-backed note financing arrangement with Royalty Pharma was established to support share repurchases and strategic acquisitions [3][5] Recent Developments - Zymeworks entered into a $250.0 million royalty-backed note financing with Royalty Pharma, allowing for greater near-term cash flow preservation [3] - The company expects to complete a supplemental Biologics License Application for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma by Q1 2026, with a potential launch in the second half of 2026 [5][8] - Zymeworks has received $53.0 million in milestone payments for Ziihera and is eligible for up to $440.0 million in additional milestone payments related to regulatory approvals in various regions [11][12] Financial Performance - Total revenue for 2025 was $106.0 million, driven by significant clinical and regulatory milestones, compared to $76.3 million in 2024 [20] - Research and development expenses for 2025 were $137.0 million, an increase from $134.6 million in 2024, primarily due to higher costs associated with clinical studies [21] - The company reported a net loss of $81.1 million for 2025, down from a net loss of $122.7 million in 2024 [24] Share Repurchase Program - The Board of Directors authorized a new share repurchase program allowing for the repurchase of up to $125.0 million in common stock [16] - As of March 2, 2026, approximately $62.5 million has been utilized to repurchase shares at an average price of $24.22 per share [17] Research and Development Focus - Zymeworks plans to continue Phase 1 clinical studies for ZW191 and ZW251 in 2026, with Investigational New Drug applications for ZW209 and ZW1528 on track for submission [6] - The company anticipates one planned IND filing per annum from its multispecific antibody portfolio starting in 2028 [6] Liquidity and Financial Outlook - As of December 31, 2025, Zymeworks had $270.6 million in cash, cash equivalents, and marketable securities, which is expected to fund operations beyond 2028 [25] - The company expects adjusted gross operating expenses to be approximately 20% lower in 2026 compared to 2025, reflecting a disciplined investment approach [18]

Company Overview - Zymeworks is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly through bispecific antibodies and antibody-drug conjugates [6] - The company has a robust pipeline and strategic partnerships with major pharmaceutical firms, providing a competitive edge in targeted oncology therapeutics [6] - As of February 17, 2026, Zymeworks has a market capitalization of $1.74 billion and reported revenue of $134.48 million with a net income of -$63.43 million [4] Recent Developments - Redmile Group significantly reduced its stake in Zymeworks by 3,214,096 shares, valued at approximately $70.10 million, as disclosed in a February 17, 2026, SEC filing [2] - The quarter-end value of Redmile's position in Zymeworks decreased by $50.35 million due to share sales and stock price movements [2] - Following the sale, Zymeworks now accounts for 0.95% of Redmile's reportable 13F assets under management (AUM) [7] Performance Metrics - Zymeworks shares were priced at $23.07 as of February 17, 2026, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 13% gain during the same period [7] - The company is eligible for up to $440 million in regulatory milestone payments tied to approvals in major markets [9] - Zymeworks ended 2025 with approximately $270.6 million in cash and marketable securities, alongside a $125 million share repurchase authorization [9] Strategic Insights - The reduction in Redmile's position is interpreted as capital recycling rather than a loss of confidence, as Zymeworks is in a transition phase balancing royalty aggregation, internal R&D, and capital returns [10] - The company continues to focus on addressing unmet medical needs in cancer treatment through licensing agreements, research collaborations, and milestone payments from strategic partners [8]